Age-related macular degeneration is the leading cause of irreversible central vision loss in older Americans; the National Eye Institute estimates that roughly 11 million people in the United States have some form of it, and prevalence climbs steeply with age. Macular degeneration attacks the small, cone-rich center of the retina responsible for reading, driving, and recognizing faces — while leaving peripheral vision intact. That is why a person with advanced AMD can navigate a hallway but cannot read a menu or see a loved one’s expression.
Recently approved drugs for geographic atrophy and an expanding pipeline of therapies have shifted the treatment landscape since 2023. This guide explains the difference between dry and wet AMD, how the disease is staged, the role of AREDS2 supplements, and what to expect from anti-VEGF injections. It is general health information, not medical advice — decisions about supplements and treatment should be made with an eye doctor who has examined you. For a wider view of senior eye health, our medical conditions hub covers related disorders.
What Macular Degeneration Is
The macula is the central portion of the retina, packed with cone photoreceptors that handle fine detail and color. In AMD, waste products called drusen accumulate beneath the retinal pigment epithelium (RPE). Over time, the RPE and overlying photoreceptors can die in a slow process called geographic atrophy (GA) — the advanced form of “dry” AMD — or, less often, abnormal blood vessels grow up from the choroid and leak fluid and blood, the hallmark of “wet” or neovascular AMD.
The American Academy of Ophthalmology and NEI describe AMD in stages: early (medium drusen, no pigment changes or symptoms), intermediate (large drusen or pigment abnormalities), and late (geographic atrophy or neovascular AMD). Most people with AMD have the dry form, and most never progress to the vision-threatening late stage. Understanding which stage you have is central to knowing whether treatment or supplements make sense — which is why staging is a job for an eye specialist, not self-diagnosis.
Risk Factors
Age is the dominant risk factor — prevalence rises sharply after 75. Family history matters: complement factor H (CFH) and ARMS2 gene variants are well-established susceptibility loci. The National Eye Institute identifies smoking as the strongest modifiable risk factor, raising risk substantially depending on how much and how long a person has smoked. White (Caucasian) ancestry, hypertension, obesity, a diet low in leafy greens, and cardiovascular disease also contribute.
The encouraging news is that some of the biggest levers are in your hands. Stopping smoking at any age slows progression and lowers risk. Mediterranean-style diets rich in lutein, zeaxanthin, omega-3 fatty acids, and dark leafy greens have shown protective associations in the AREDS2 cohort and other longitudinal studies. Controlling blood pressure and staying physically active support overall retinal and vascular health. None of these guarantee prevention, but together they meaningfully shift the odds.
Symptoms by Stage
Early AMD is usually asymptomatic and detected only on a dilated exam. Intermediate disease can produce mild blurring of central vision, slower dark adaptation when entering a dim room, and the sense that print “moves” or “fades.” Late dry AMD causes a slowly enlarging blind spot — patients describe missing letters in the middle of words or no longer recognizing faces unless they look slightly off-center.
Wet AMD often announces itself abruptly. Straight lines appear wavy or bent (a phenomenon called metamorphopsia), a dark or distorted spot grows over days to weeks, and color perception dims. The Amsler grid — a printed graph patients view at home, one eye at a time — is designed to catch these changes early. Any new distortion or metamorphopsia warrants a same-week ophthalmology evaluation, because anti-VEGF therapy is most effective before significant scarring occurs. If you already have AMD, ask your eye doctor how often to check your Amsler grid and what changes should trigger a call.
When to seek emergency care: Call 911 or go to the emergency room for sudden, painless loss of central or peripheral vision, a curtain across the field, flashes with new floaters, or severe eye pain with nausea. These point to retinal detachment, vitreous hemorrhage, or acute angle-closure glaucoma rather than typical AMD progression, and they are time-critical.
How AMD Is Diagnosed
A dilated fundus exam reveals drusen, pigment changes, geographic atrophy, and signs of neovascularization. Optical coherence tomography (OCT) provides cross-sectional imaging of the retinal layers and is the workhorse for detecting and monitoring fluid in wet AMD. Fluorescein angiography or OCT angiography maps abnormal vessels when neovascularization is suspected. Fundus autofluorescence highlights areas of RPE loss and is used to track GA growth over time.
Genetic testing is not recommended for routine clinical care, per AAO guidelines, because results do not currently change management. If you are offered a direct-to-consumer genetic test that promises to guide your AMD care, discuss it with your ophthalmologist before spending money on it.
Treatment of Dry AMD
For intermediate dry AMD — or late AMD in one eye with intermediate disease in the fellow eye — the AREDS2 formulation reduces the five-year risk of progression to advanced AMD by roughly a quarter in the trial population. According to the AAO, the formula contains 500 mg vitamin C, 400 IU vitamin E, 80 mg zinc, 2 mg copper, 10 mg lutein, and 2 mg zeaxanthin. AREDS2 trial data showed that beta-carotene increased lung cancer risk in current and former smokers, so it was replaced with lutein and zeaxanthin — which is why smokers and former smokers in particular should use the AREDS2 (not the original AREDS) formulation. These supplements do not prevent AMD in people without it, and they are not recommended for early AMD; confirm with your eye doctor that you fit the group shown to benefit before starting.
Until recently, no treatment slowed geographic atrophy. The FDA approvals of pegcetacoplan (Syfovre) in February 2023 and avacincaptad pegol (Izervay) in August 2023 — both intravitreal complement inhibitors — modestly slow GA expansion in clinical trials. Importantly, they do not restore lost vision, they require ongoing injections, and they carry risks including new-onset wet AMD, intraocular inflammation, and, rarely, ischemic optic neuropathy. Whether and when to start these drugs is an evolving, individualized discussion with a retina specialist. Because this area is changing quickly, verify the current options and evidence with your ophthalmologist.
Treatment of Wet AMD
Anti-VEGF intravitreal injections transformed the wet AMD prognosis. Aflibercept (Eylea, including the higher-dose Eylea HD), ranibizumab (Lucentis and biosimilars), bevacizumab (Avastin, used off-label but extensively), brolucizumab (Beovu), and faricimab (Vabysmo) all suppress vascular endothelial growth factor and reduce leakage. Most patients receive frequent injections initially, then move to a “treat-and-extend” schedule that stretches the interval between visits as the disease stabilizes.
With treatment, most patients avoid significant vision loss at one year, and a meaningful share gain lines of vision on the eye chart; untreated wet AMD typically progresses to severe central vision loss in the affected eye. Injections are quick and done under numbing drops; serious complications such as endophthalmitis (a rare but sight-threatening infection) occur in only a small fraction of injections. The main practical burden is the ongoing schedule of visits — treatment usually continues for years, and stopping often allows the disease to recur.
Living With AMD: Low-Vision Resources
When vision loss limits daily function, low-vision rehabilitation can dramatically extend independence. Magnifiers, e-readers with adjustable contrast, high-contrast lighting, eccentric-viewing training, and screen-reader software all help. Medicare covers certain low-vision rehabilitation services when prescribed appropriately; check your specific coverage before assuming a device or service is included. Driving generally becomes unsafe once central acuity drops below your state’s licensing threshold — a practical bridge to broader concerns covered in our driving safety guide for older adults.
Social engagement matters more than people expect. Vision impairment can make it harder to stay connected, and social isolation is associated with worse health outcomes among older adults. National and state organizations for the blind and visually impaired offer free training, support groups, and adaptive-technology resources; ask your ophthalmologist or optometrist for a referral to low-vision services in your area.
Frequently Asked Questions
Does macular degeneration cause total blindness?
AMD spares peripheral vision. Even with advanced disease, most people retain enough side vision to navigate familiar spaces. Legal blindness (central acuity of 20/200 or worse) is possible, but complete darkness is not a typical outcome of AMD alone.
Should I take AREDS2 vitamins if I only have early AMD?
The AREDS2 trial found benefit for intermediate AMD, or advanced AMD in one eye — not for early AMD. Routine supplementation for early AMD is not currently recommended by the AAO. A retina specialist or ophthalmologist can stage your disease and tell you whether you fit the group that benefits.
Is wet AMD curable?
Anti-VEGF injections suppress the abnormal blood vessels and preserve vision, but they do not cure the underlying degeneration. Most patients require ongoing injections for years, and stopping treatment usually allows recurrence within months.
Can lifestyle changes reverse macular degeneration?
No intervention reverses established drusen or atrophy. Smoking cessation, blood pressure control, a Mediterranean-style diet, and AREDS2 supplements (when indicated) can slow progression. The earlier these are adopted, the better the likely trajectory.
How often should I have my eyes checked if I have AMD?
Adults over 60 generally benefit from periodic dilated exams, and people with diagnosed AMD are typically monitored more often — sometimes every 6 to 12 months, or sooner if symptoms change. Your eye doctor will set a schedule based on your stage and risk. Between visits, use your Amsler grid and report any new distortion promptly.
The Bottom Line
Macular degeneration is the leading cause of irreversible central vision loss in older Americans, but the outlook today is meaningfully better than it was a decade ago. Dilated exams — yearly for most older adults and more often once intermediate AMD is identified — catch conversion to wet AMD before it scars. AREDS2 supplements help selected patients, complement inhibitors now offer options for geographic atrophy, and anti-VEGF therapy preserves driving and reading vision in most patients with neovascular disease. Use an Amsler grid, do not smoke, and call your eye doctor the day distortion appears.
The short version: AMD damages central vision but usually spares side vision, and comes in dry (most common) and wet forms. Age, smoking, and family history drive risk — not smoking is the biggest thing you control. Sudden wavy or distorted vision may mean wet AMD and needs a prompt eye exam, because anti-VEGF injections work best before scarring. AREDS2 supplements can slow intermediate dry AMD under an eye doctor’s guidance, and new drugs can slow geographic atrophy. There’s no cure, but treatment preserves vision — see an ophthalmologist and use an Amsler grid at home.
This article is general educational information, not medical advice, and it does not replace an examination by a qualified eye care professional. Treatments and evidence in AMD are changing quickly; verify current options with your ophthalmologist and authoritative sources such as the National Eye Institute and the American Academy of Ophthalmology. For sudden vision loss, seek urgent care.
Sources
- National Eye Institute, NIH — Age-related macular degeneration (nei.nih.gov)
- American Academy of Ophthalmology — AMD: diagnosis and treatment (aao.org)
- National Eye Institute — Age-Related Eye Disease Studies (AREDS/AREDS2) (nei.nih.gov)
- U.S. Food and Drug Administration — approvals of geographic atrophy (pegcetacoplan/Syfovre; avacincaptad pegol/Izervay) and anti-VEGF therapies (fda.gov)